Therapeutic | Coltuximab |
Target | CD19 |
Heavy Chain | QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS |
Light Chain | EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK |
100% seqID Fv Structure | 6ani [Fvs: HL, IM] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6ani [Fvs: HL, IM] |
Follow these links to our prediction tools:
Format | Whole mAb ADC |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2013 |
INN Year Recommended | 2014 |
Companies Involved | ImmunoGen |
Conditions Approved | na |
Conditions Active | Diffuse large B cell lymphoma |
Conditions Discontinued | Precursor cell lymphoblastic leukaemia-lymphoma |
Notes |